Skip to main content
Clinical Trials/ISRCTN10499680
ISRCTN10499680
Active, not recruiting
未知

A feasibility study evaluating the efficacy of indwelling pleural catheters plus sclerosant in persistent symptomatic pleural effusions secondary to heart failure

orth Bristol NHS Trust0 sites18 target enrollmentAugust 12, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
Recurrent pleural effusion secondary to heart failure
Sponsor
orth Bristol NHS Trust
Enrollment
18
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 12, 2021
End Date
October 12, 2024
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
orth Bristol NHS Trust

Eligibility Criteria

Inclusion Criteria

  • 1\. The presence of a recurrent pleural effusion secondary to heart failure that has not responded to medical therapy
  • 2\. Sufficient pleural fluid for IPC insertion
  • 3\. Symptomatic breathlessness warranting pleural intervention
  • 4\. Pleural infection excluded to satisfaction of treating physician
  • 5\. Expected survival \>12 weeks
  • 6\. Written informed consent to trial participation

Exclusion Criteria

  • 1\. Age \<18 years
  • 2\. Known pleural malignancy
  • 3\. Pregnancy, lactation or intention to become pregnant
  • 4\. Absolute contraindication to IPC insertion or therapeutic aspiration of pleural fluid
  • 5\. Previous attempts at ipsilateral pleurodesis
  • 6\. Evidence of extensive lung entrapment on chest x\-ray or CT, or significant fluid loculation on ultrasound scan, to a level which would normally be a contraindication to attempted talc pleurodesis or IPC insertion.
  • 7\. Inability to give informed consent
  • 8\. Patient has no access to a telephone

Outcomes

Primary Outcomes

Not specified

Similar Trials